• Jasper Therapeutics launched a comprehensive review of strategic alternatives to maximize shareholder value.
• Options under evaluation include asset sales or licensing, partnerships, a company sale, or a merger or other strategic transaction.
• Management will pursue additional cost cuts to preserve cash while maintaining regulatory and financial reporting compliance.
• No timeline was set for the review, with no assurance a transaction will be announced or completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-063157), on June 01, 2026, and is solely responsible for the information contained therein.